Lumen Technologies hires Sean Alexander as head of Connected Ecosystems
Investing.com -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV) stock surged 18% following the announcement of positive topline data from its Phase I/II trial evaluating Allocetra in patients with moderate-to-severe knee osteoarthritis.
The multi-center, double-blind, randomized, placebo-controlled clinical trial showed promising results at the three-month mark. In the overall modified intention-to-treat population, patients in the Allocetra treatment arm experienced a 24% reduction in knee pain and 26% improvement in knee function compared to placebo.
More notably, age-related primary osteoarthritis patients showed substantially stronger responses, with a 72% reduction in knee pain and 95% improvement in knee function versus placebo. These results represent statistically significant improvements in commonly used Phase III primary endpoints for knee osteoarthritis trials.
The treatment demonstrated a favorable safety profile with no severe adverse events reported. Side effects were generally limited to mild or moderate, transient, and treatable conditions in most patients receiving Allocetra.
"We believe these results provide clear indication that Allocetra has the potential to become a novel, safe and effective treatment for knee osteoarthritis, a growing market with significant unmet medical need," said Oren Hershkovitz, Ph.D, CEO of Enlivex.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.